Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01130064 · ClinicalTrials.gov registry record · Phase 2
Efficacy of QAX576 in Asthma
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 259
- Enrollment target
NCT01130064 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 259 participants.
The verdict
NCT01130064, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 259 participants
- Enrollment target
Study Summary
The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.
Interventions
- DRUG Placebo
- BIOLOGICAL QAX576
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 259 participants |
| Start Date | 2010-05 |
| Est. Completion | 2012-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01130064
The ClinicalTrials.gov registry entry for NCT01130064 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 259 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01130064 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01130064 about?
NCT01130064 is a clinical study titled "Efficacy of QAX576 in Asthma". The purpose of this study is to investigate the efficacy of 24 weeks intravenous treatment with QAX576 in patients with persistent asthma not adequately controlled with inhaled corticosteroids and long acting beta2-agonists.
What is the current status of trial NCT01130064?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 259 participants. The study started on 2010-05. Estimated completion is 2012-04.
What interventions are being tested in trial NCT01130064?
The interventions under investigation include: Placebo (DRUG), QAX576 (BIOLOGICAL).
Who is sponsoring clinical trial NCT01130064?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.